Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Nippon Shinyaku Licenses OAB Drug from DSP, Aims for Launch of Nocturia Treatment in 2019
March 11, 2013
- Takeda Files for UC and CD Drug Vedolizumab in Europe
March 11, 2013
- Otsuka, Lundbeck to Expand Collaboration, Copromote Abilify in US, Europe
March 11, 2013
- Ethical Drug Sales Up 4.8% in January: Crecon Report
March 11, 2013
- Astellas, UCB Japan Launch RA Treatment Cimzia
March 11, 2013
- NBI Calls for Proper Use of Prazaxa due to Unsatisfactory Compliance with Blue Letter
March 11, 2013
- Sandoz Will See Accelerated Growth of Japan Operations in 2013: Global Head
March 11, 2013
- Eisai to Reorganize Sales Force in Japan to Secure Aricept Market Share
March 8, 2013
- With Growing Competition from Foreign Drug Makers, Takeda Interested in Product Tie-ups: President Hasegawa
March 8, 2013
- Yakult Enters Biosimilars Business, Ties Up with UMN and API
March 7, 2013
- Novartis Withdraws Application for Glivec for PAH in Japan
March 7, 2013
- Ajinomoto to Acquire US Contract Biologic Manufacturer Althea
March 7, 2013
- Sawai's New Plant Starts Operation, Raising Annual Production Capacity to 8 Billion Tablets
March 6, 2013
- Nichi-Iko's New Factory Completed in Toyama, Production Capacity to Reach 7-8 Billion Tablets a Year
March 6, 2013
- DSP to Merge Its Clinical Development Functions with US Subsidiary’s
March 6, 2013
- Ranbaxy Resumes Production of Atorvastatin at US Plant
March 6, 2013
- 2 SGLT-2 Inhibitors to Be Filed for Approval without Concurrent-Use Restrictions
March 5, 2013
- Pfizer Positive about In-Licensing Other Firms’ Long-Listed Drugs: VP Matsumori
March 5, 2013
- 3-Drug H. pylori Eradication Therapies to Get Further Indication for Chronic Gastritis; Big Boost to PPI Market Expected
March 5, 2013
- Daiichi Sankyo to Set Up Biologics Oversight Function within R&D Division in Order to Enhance Biopharmaceutical Research Level
March 5, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…